Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.

Patents 267show all

  • 87
    A61K - Preparations for medical, dental, or toilet purposes
  • 68
    C07D - Heterocyclic compounds
  • 12
    C08F - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
  • 8
    B82Y - Specific uses or applications of nanostructures
  • 4
    C07C - Acyclic or carbocyclic compounds
  • 4
    C12N - Microorganisms or enzymes
  • 2
    C07H - Sugars
  • 2
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 2
    C12Y - Enzymes
  • 1
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations

Clinical Trials 11show all

7Phase 24Phase 1/Phase 2

SEC Filings show all


113
8-K

36
10-Q

11
10-K

1
D

Contact Information

15245 Shady Grove Road, Suite 455
Rockville, MD 20850
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$5,000,00011-502013-10-13Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2013-10-13$5,000,000Series Unknown

SEC Form D Funding Events

DateOfferedSoldType
2008-01-08Unknown Unknown Other (Paper Filing)